PofoliaShared via Pofolia

Archives of Toxicology· 2026Q1

Comparative in vitro metabolic profiling of six novel methylthiophene cathinones using different human liver systems and LC-HRMS/MS

Tilman F. Arnst, Iris E. Weber, Selina Hemmer, Simon D. Brandt et al.

Short summary

Six novel methylthiophene cathinones were metabolically profiled in human liver microsomes, S9 fractions, and HepG2 cells, revealing 48 phase I and two phase II metabolites, with 5'-methylhydroxylated products and parent compounds identified as key analytical targets.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Six novel methylthiophene cathinones were analyzed for their in vitro hepatic metabolism.
  • 48 phase I and two phase II metabolites were tentatively identified using pooled human liver microsomes, S9 fraction, and HepG2 cells.
  • Hydroxylation at the 5'-methyl group was a common metabolic pathway across all tested human liver systems.
  • CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP3A4 were identified as key enzymes involved in the initial metabolic steps.

AI-generated from the title and abstract; the full text is not read.

Abstract

Abstract Synthetic cathinones represent a major class of new psychoactive substances associated with severe toxicological risks. Therapeutic cathinone derivatives such as amfepramone (appetite suppressant) were partially removed from the market due to severe side effects. p -Tolyl-substituted synthetic cathinones are primarily known as new psychoactive substances and are associated with serious adverse events and abuse liability. Bioisosteric replacement of the p -tolyl ring with a 5′-methylthiophene moiety has recently emerged as a structural optimization strategy in this class and has led to the evaluation of methylthiophenes, a novel class of cathinone analogues. Knowledge of their hepatic biotransformation is essential for reliable toxicological detection and risk assessment. This study investigated the in vitro hepatic metabolism of six novel methylthiophene cathinones, 5Me-NM-BT (5-methyl- N -methyl-butanothiophenone), 5Me-NM-VT (5-methyl- N -methyl-valerothiophenone), 5Me-NE-BT (5-methyl- N -ethyl-butanothiophenone), 5Me-NE-VT (5-methyl- N -ethyl-valerothiophenone), 5Me- α P-BT (5-methyl- α -pyrrolidino-butanothiophenone), and 5Me- α P-VT (5-methyl- α -pyrrolidino-valerothiophenone) using pooled human liver microsomes (pHLM), pooled human liver S9 fraction (pHLS9), and HepG2 cells. Metabolites were characterized using reversed-phase and hydrophilic interaction liquid chromatography coupled to high-resolution tandem mass spectrometry. Additionally, recombinant human monooxygenases were screened to identify isoenzymes mediating initial phase I steps. In total, 48 phase I and two phase II metabolites could be tentatively identified. Within each subgroup, the compounds showed similar metabolic profiles. Isozyme mapping revealed consistent contributions of various enzymes, including CYP1A2, CYP2B6, CYP2C19, CYP2D6, and CYP3A4 suggesting a low risk of metabolism-based drug–drug interactions or single-enzyme polymorphism impact. Hydroxylated metabolites at the 5′-methyl group were consistently abundant across all models and, in combination with the respective parent compounds, represent promising analytical targets for toxicological screening.

The authors' abstract, as published at the source. Archives of Toxicology, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

ToxicologyPharmacology, Toxicology and Pharmaceutics